EGFR and non-small cell lung carcinoma: On the one hand, major large prospective clinical studies exploring the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in the first-line treatment of advanced NSCLC were restricted to common EGFR mutations, including FLAURA study (osimertinib versus gefitinib or erlotinib) [6], and ARCHER 1050 study (dacomitinib versus gefitinib) [7].